Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	48 people with "annoying tinnitus" In review	Proportion of people with dizziness 30 days 8/24 (33%) with carbamazepine (150 mg three times/day for 30 days) 0/24 (0%) with placebo	Significance not assessed
RCT	48 people with "annoying tinnitus" In review	Proportion of people with nausea 30 days 8/24 (33%) with carbamazepine (150 mg three times/day for 30 days) 0/24 (0%) with placebo	Significance not assessed
RCT	48 people with "annoying tinnitus" In review	Proportion of people with headache 30 days 4/24 (17%) with carbamazepine (150 mg three times/day for 30 days) 1/24 (4%) with placebo	Significance not assessed
RCT	48 people with "annoying tinnitus" In review	Proportion of people reporting tiredness 30 days 2/24 (8%) with carbamazepine (150 mg three times/day for 30 days) 0/24 (0%) with placebo	Significance not assessed
RCT	48 people with "annoying tinnitus" In review	Proportion of people with vomiting 30 days 2/24 (8%) with carbamazepine (150 mg three times/day for 30 days) 0/24 (0%) with placebo	Significance not assessed
RCT	48 people with "annoying tinnitus" In review	Proportion of people with diarrhoea 30 days 1/24 (4%) with carbamazepine (150 mg three times/day for 30 days) 0/24 (0%) with placebo	Significance not assessed